These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 25802198)
1. Use of Activated Factor VII in Patients with Diffuse Alveolar Hemorrhage: A 10 Years Institutional Experience. Pathak V; Kuhn J; Gabriel D; Barrow J; Jennette JC; Henke DC Lung; 2015 Jun; 193(3):375-9. PubMed ID: 25802198 [TBL] [Abstract][Full Text] [Related]
2. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Heslet L; Nielsen JD; Levi M; Sengeløv H; Johansson PI Crit Care; 2006; 10(6):R177. PubMed ID: 17184515 [TBL] [Abstract][Full Text] [Related]
3. Intrapulmonary Recombinant Factor VII as an Effective Treatment for Diffuse Alveolar Hemorrhage: A Case Series. Baker MS; Diab KJ; Carlos WG; Mathur P J Bronchology Interv Pulmonol; 2016 Jul; 23(3):255-8. PubMed ID: 27261934 [TBL] [Abstract][Full Text] [Related]
4. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Hicks K; Peng D; Gajewski JL Bone Marrow Transplant; 2002 Dec; 30(12):975-8. PubMed ID: 12476294 [TBL] [Abstract][Full Text] [Related]
5. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Phillips LE; McLintock C; Pollock W; Gatt S; Popham P; Jankelowitz G; Ogle R; Cameron PA; Anesth Analg; 2009 Dec; 109(6):1908-15. PubMed ID: 19923520 [TBL] [Abstract][Full Text] [Related]
6. Intrapulmonary recombinant factor VIIa for diffuse alveolar hemorrhage in children. Park JA; Kim BJ Pediatrics; 2015 Jan; 135(1):e216-20. PubMed ID: 25548333 [TBL] [Abstract][Full Text] [Related]
7. Treatment of diffuse alveolar hemorrhage in systemic lupus erythematosus patient with local pulmonary administration of factor VIIa (rFVIIa): a case report. Alabed IB Medicine (Baltimore); 2014 Sep; 93(14):e72. PubMed ID: 25255019 [TBL] [Abstract][Full Text] [Related]
8. Treatment of Diffuse Alveolar Hemorrhage: Controlling Inflammation and Obtaining Rapid and Effective Hemostasis. Park JA Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466873 [TBL] [Abstract][Full Text] [Related]
9. Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation. Elinoff JM; Bagci U; Moriyama B; Dreiling JL; Foster B; Gormley NJ; Salit RB; Cai R; Sun J; Beri A; Reda DJ; Fakhrejahani F; Battiwalla M; Baird K; Cuellar-Rodriguez JM; Kang EM; Pavletic SZ; Fowler DH; John Barrett A; Lozier JN; Kleiner DE; Mollura DJ; Childs RW; Suffredini AF Biol Blood Marrow Transplant; 2014 Jul; 20(7):969-78. PubMed ID: 24657447 [TBL] [Abstract][Full Text] [Related]
10. Pulmonary administration of activated recombinant factor VII. Grochova M; Kalnasova B; Firment J; Olejarova I; Roland R; Lazurova I Bratisl Lek Listy; 2011; 112(1):29-33. PubMed ID: 21452776 [TBL] [Abstract][Full Text] [Related]
11. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474 [TBL] [Abstract][Full Text] [Related]
12. Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events. Brophy GM; Candeloro CL; Robles JR; Brophy DF Ann Pharmacother; 2013 Apr; 47(4):447-54. PubMed ID: 23535812 [TBL] [Abstract][Full Text] [Related]
13. Applicability and safety of recombinant activated factor VII to control non-haemophilic haemorrhage: investigational experience in 265 children. Herbertson M; Kenet G Haemophilia; 2008 Jul; 14(4):753-62. PubMed ID: 18445016 [TBL] [Abstract][Full Text] [Related]
15. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7). Hacquard M; Durand M; Lecompte T; Boini S; Briançon S; Carteaux JP Eur J Cardiothorac Surg; 2011 Dec; 40(6):1320-7. PubMed ID: 21550261 [TBL] [Abstract][Full Text] [Related]
16. Surgery in patients with congenital factor VII deficiency - a single center study. Szczepanik A; Wiszniewski A; Oses-Szczepanik A; Dąbrowski W; Pielaciński K; Misiak A Pol Przegl Chir; 2018 May; 90(5):1-5. PubMed ID: 30426948 [TBL] [Abstract][Full Text] [Related]
17. Pilot trial of a novel two-step therapy protocol using nebulized tranexamic acid and recombinant factor VIIa in children with intractable diffuse alveolar hemorrhage. Bafaqih H; Chehab M; Almohaimeed S; Thabet F; Alhejaily A; AlShahrani M; Zolaly MA; Abdelmoneim AA; Abd ES Ann Saudi Med; 2015; 35(3):231-9. PubMed ID: 26409798 [TBL] [Abstract][Full Text] [Related]
19. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Brady KM; Easley RB; Tobias JD Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833 [TBL] [Abstract][Full Text] [Related]
20. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications. Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]